Tofacitinib in Juvenile Idiopathic Arthritis

Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Study ID
NCT07211932
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Juvenile Idiopathic Arthritis (JIA)

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Study Details

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Key Dates

Start date
Dec 31, 2025
Status verified
Oct 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
58 participants (estimated)

Arms

  • Arm: Tofacitinib
    Patients affected by JIA and treated with tofacitinib

Primary Outcome Measure

JADAS-10 [ Time Frame: Baseline and 12 months ]

Central Contacts

Related Studies